The 16 analysts offering 1 year price forecasts for CYTK have a max estimate of — and a min estimate of —.
Analyst rating
Based on 18 analysts giving stock ratings to CYTK in the past 3 months.
EPS
0.00
Reported
Estimate
Reported
Estimate
Surprise
Revenue
0.00
Reported
Estimate
Reported
Estimate
Surprise
Be warned
This info isn't a recommendation for what you should personally do, so please don't take the data as investment advice. As with any trade, always look first, then leap. Read more in the Terms of Use.
Frequently Asked Questions
CYTK EPS for the last quarter is −1.36 USD despite the estimation of −1.23 USD. In the next quarter EPS is expected to reach −1.27 USD. Track more of Cytokinetics, Incorporated financials and stay on top of what is up with the company.
According to analysts, CYTK price target is 81.63 USD with a max estimate of 120.00 USD and a min estimate of 60.00 USD. Check if this forecast comes true in a year, meanwhile watch Cytokinetics, Incorporated stock price chart and keep track of the current situation with CYTK news and stock market news.
We've gathered opinions of 18 analysts rating CYTK stock in the past 3 months. Most of them backed up the strong buy trend, and after taking into account other opinions, the overall rating was calculated as buy. Note that it's not a trading advice — your own analysis is still required.